Form 4: Collegium Pharmaceutical EVP Thomas B. Smith Reports Changes in Beneficial Ownership

EVP and Chief Medical Officer of Collegium Pharmaceutical, Thomas B. Smith, reports acquisition and disposal of company stock and vesting of restricted stock units and performance share units.

Summary

• Thomas B. Smith, EVP and Chief Medical Officer of Collegium Pharmaceutical, filed a Form 4 detailing changes in beneficial ownership.
• On February 10, 2025, Smith acquired 33,762 shares of common stock through restricted stock units (RSUs) and 5,313 shares through performance share units (PSUs).
• He also disposed of 1,498 shares and 4,399 shares to cover withholding taxes upon the vesting of PSUs and RSUs, respectively, at a price of $30.52 per share.
• Following these transactions, Smith beneficially owns 87,742 shares of Collegium Pharmaceutical common stock.
• The RSUs vest over three years, starting February 10, 2026, subject to continued service.
• The filing also notes the acquisition of 373 and 375 shares under the employee stock purchase plan on July 19, 2024, and January 17, 2025, respectively.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation. There are no explicit positive or negative indicators, but the continued vesting suggests ongoing performance.

Positives

• The vesting of RSUs and PSUs indicates that the company is meeting performance targets and rewarding its executives.
• The executive's continued holding of a significant number of shares (87,742) suggests confidence in the company's future prospects.

Negatives

• The disposal of shares to cover withholding taxes, while standard practice, slightly reduces the executive's stake in the company.

Risks

• The vesting of RSUs is contingent upon the Reporting Person's continued service with the Issuer, creating a potential risk if the Reporting Person leaves the company.
• Fluctuations in the stock price could impact the value of the vested shares.

Future Outlook

The RSUs will continue to vest in equal annual installments over the two-year period following February 10, 2026, contingent upon continued service.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders. This filing is typical for executives receiving stock-based compensation.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the pharmaceutical industry to align executive interests with shareholder value.
• Vesting schedules for RSUs and PSUs are generally structured to incentivize long-term performance and retention, similar to practices at companies like Amgen, Gilead Sciences, and Biogen.
• The specific vesting criteria for PSUs would need to be compared to industry benchmarks to assess their rigor and alignment with company goals.

Stakeholder Impact

• Shareholders may view the vesting of RSUs and PSUs as a positive sign, indicating that executives are incentivized to improve company performance.
• Employees may be motivated by the company's use of stock-based compensation.

Next Steps

• Continued monitoring of insider transactions to assess executive sentiment and potential impact on stock price.
• Tracking the vesting of RSUs and PSUs over the next few years.

Key Dates